Walgreens, Walmart and CVS told a federal appeals panel on Thursday that the reasoning behind an opioid abatement fund awarded to two Ohio counties, if extrapolated, would put them on the hook for nearly $500 billion in public health costs nationwide.
In an opening brief with the U.S. Court of Appeals for the Sixth Circuit, the three pharmacies sought to overturn a 2021 jury verdict and subsequent $650 million abatement award, to be paid over 15 years. The pharmacies’ lawyers contend U.S. District Judge Dan Polster of the Northern District of Ohio’s “unprecedented” abatement award, issued on Aug. 17, would impermissibly “fund a comprehensive slate of government public-health programs designed to address the broad downstream health, social, and criminal-justice effects of the opioid crisis for the next half-generation.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
